WO2017200369A3 - Uso del péptido gk-1 como un agente anti-tumoral y/o anti-metastásico - Google Patents

Uso del péptido gk-1 como un agente anti-tumoral y/o anti-metastásico Download PDF

Info

Publication number
WO2017200369A3
WO2017200369A3 PCT/MX2017/000055 MX2017000055W WO2017200369A3 WO 2017200369 A3 WO2017200369 A3 WO 2017200369A3 MX 2017000055 W MX2017000055 W MX 2017000055W WO 2017200369 A3 WO2017200369 A3 WO 2017200369A3
Authority
WO
WIPO (PCT)
Prior art keywords
antitumoral
peptide
cancer
antimetastatic agent
treatment
Prior art date
Application number
PCT/MX2017/000055
Other languages
English (en)
French (fr)
Other versions
WO2017200369A2 (es
Inventor
Edda Lydia SCIUTTO CONDE
Gladis Del Carmen FRAGOSO GONZÁLEZ
Diana TORRES GARCÍA
Jacquelynne Brenda CERVANTES TORRES
René Alvaro SEGURA VELÁZQUEZ
Armando PÉREZ TORRES
Karen Manucharyan
Original Assignee
Universidad Nacional Autónoma de México
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad Nacional Autónoma de México filed Critical Universidad Nacional Autónoma de México
Priority to US16/302,786 priority Critical patent/US11020449B2/en
Priority to EP17799725.1A priority patent/EP3459557B1/en
Publication of WO2017200369A2 publication Critical patent/WO2017200369A2/es
Publication of WO2017200369A3 publication Critical patent/WO2017200369A3/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere al uso del péptido que presenta la secuencia de aminoácidos G-Y-Y-Y-P-S-D-P-N-T-F-Y-A-P-P-Y-S-A denominado GK-1 para su uso como un agente antitumoral y antimetátasica o para el tratamiento de cáncer específicamente de células cancerosas de células basales, de células escamosas, carcinoma de células de transición y adenocarcinoma, y de preferencia para el tratamiento de cáncer de mama.
PCT/MX2017/000055 2016-05-18 2017-05-18 Uso del péptido gk-1 como un agente anti-tumoral y/o anti-metastásico WO2017200369A2 (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US16/302,786 US11020449B2 (en) 2016-05-18 2017-05-18 Use of the GK-1 peptide as an antitumoral and/or antimetastatic agent
EP17799725.1A EP3459557B1 (en) 2016-05-18 2017-05-18 Use of the gk-1 peptide as an antitumoral and/or antimetastatic agent

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX2016006460A MX2016006460A (es) 2016-05-18 2016-05-18 Uso del peptido gk-1 como un agente anti-tumoral y/o anti-metastasico.
MXMX/A/2016/006460 2016-05-18

Publications (2)

Publication Number Publication Date
WO2017200369A2 WO2017200369A2 (es) 2017-11-23
WO2017200369A3 true WO2017200369A3 (es) 2018-01-11

Family

ID=60325378

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/MX2017/000055 WO2017200369A2 (es) 2016-05-18 2017-05-18 Uso del péptido gk-1 como un agente anti-tumoral y/o anti-metastásico

Country Status (4)

Country Link
US (1) US11020449B2 (es)
EP (1) EP3459557B1 (es)
MX (1) MX2016006460A (es)
WO (1) WO2017200369A2 (es)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05003413A (es) * 2005-03-31 2007-02-22 Univ Mexico Nacional Autonoma Uso del peptido gk-1 para potencial la respuesta inmunologica generada por la vacuna de influenza.
WO2013015668A2 (es) * 2011-07-26 2013-01-31 Universidad Nacional Autonoma De Mexico Uso del péptido gk-1 expresado en el fago filamentoso m13 para la elaboración de productos farmacéuticos que aumentan la eficiencia de la respuesta inmune inducida por antígenos vacunales o patógenos

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05003413A (es) * 2005-03-31 2007-02-22 Univ Mexico Nacional Autonoma Uso del peptido gk-1 para potencial la respuesta inmunologica generada por la vacuna de influenza.
WO2013015668A2 (es) * 2011-07-26 2013-01-31 Universidad Nacional Autonoma De Mexico Uso del péptido gk-1 expresado en el fago filamentoso m13 para la elaboración de productos farmacéuticos que aumentan la eficiencia de la respuesta inmune inducida por antígenos vacunales o patógenos

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GEVORKIAN G ET AL.: "Immunodominant synthetic peptides of Taenia crassiceps in murine and human cysticercosis", IMMUNOLOGY LETTERS, vol. 49, no. 3, 30 November 1995 (1995-11-30), pages 185 - 189, XP001058409, ISSN: 0165-2478 *
PEREZ-TORRES ARMANDO ET AL.: "Hematological Effects, Serum, and Pulmonary Cytokine Profiles in a Melanoma Mouse Model Treated with GK1", CANCER BIOTHERAPY & RADIOPHARMACEUTICALS, vol. 30, no. 6, 31 July 2015 (2015-07-31), pages 247 - 254, XP055451084, ISSN: 1084-9785 *
PEREZ-TORRES ARMANDO ET AL.: "The Synthetic Parasite-Derived Peptide GK1 Increases Survival in a Preclinical Mouse Melanoma Model", CANCER BIOTHERAPY & RADIOPHARMACEUTICALS, vol. 28, no. 9, 31 October 2013 (2013-10-31), pages 682 - 690, XP055451113, ISSN: 1084-9785 *
PINON-ZARATE GABRIELA ET AL.: "GK-1 Improves the Immune Response Induced by Bone Marrow Dendritic Cells Loaded with MAGE-AX in Mice with Melanoma", JOURNAL OF IMMUNOLOGY RESEARCH 2014, 30 November 2013 (2013-11-30), pages 158980, XP055451090, ISSN: 2314-8861 *
VERA-AGUILERA JESUS ET AL.: "Novel Treatment of Melanoma: Combined Parasite-Derived Peptide GK-1 and Anti-Programmed Death Ligand 1 Therapy", CANCER BIOTHERAPY & RADIOPHARMACEUTICALS, vol. 32, no. 2, 28 February 2017 (2017-02-28), pages 49 - 56, XP055451111, ISSN: 1084-9785 *

Also Published As

Publication number Publication date
EP3459557A2 (en) 2019-03-27
US20200222495A1 (en) 2020-07-16
EP3459557B1 (en) 2022-04-27
EP3459557A4 (en) 2019-10-02
US11020449B2 (en) 2021-06-01
MX2016006460A (es) 2017-11-17
WO2017200369A2 (es) 2017-11-23

Similar Documents

Publication Publication Date Title
WO2017134302A3 (en) Targeted therapeutic agents and uses thereof
EP3736294A3 (en) Cd73 blockade
NZ732211A (en) Combination immunotherapy approach for treatment of cancer
WO2016134335A3 (en) Pvrig polypeptides and methods of treatment
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2021014286A (es) Proteinas multiespecificas.
MX2019015311A (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
PH12015501983B1 (en) Peptides and compositions for treatment of joint damage
EP4257152A3 (en) Apelin polypeptides
PH12018502714A1 (en) Nicotine particles and compositions
EA201990298A1 (ru) Способы и композиции для лечения рака
WO2015132675A3 (en) Methods and compositions for modifying the immune response
MX2017006437A (es) Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor.
MX2018002546A (es) Composiciones que comprenden un compuesto de urolitina.
WO2016014342A3 (en) Ang-(1-7) derviative oligopeptides and methods for using and producing the same
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
MX2017010883A (es) Composicion para el tratamiento de la infertilidad.
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
PH12021550122A1 (en) Solubilized apyrases, methods and use
MX2017006513A (es) Compuestos de tipo 1,9-diazaespiroundecano con actividad multimodal contra el dolor.
MX2015002279A (es) Peptido pntx(19) sintético, composición farmacéutica.y uso.
WO2019016597A3 (en) SYNTHETIC PROTEINS AND THEIR THERAPEUTIC USES
EA201690966A1 (ru) Новое соединение для лечения тяжелой гипогликемии
MX2017003949A (es) Derivados peptidicos novedosos y sus usos.
MX2017002277A (es) Anticuerpos que potencian el factor h y sus usos.

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17799725

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2017799725

Country of ref document: EP

Effective date: 20181218